Victory Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Victory Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,792	Closed	-$313K	–	2610
2022 Q3	$313K	Hold	4,792	–	–	﹤0.01%	2235
2022 Q2	$291K	Hold	4,792	–	–	﹤0.01%	2245
2022 Q1	$238K	Hold	4,792	–	–	﹤0.01%	2371
2021 Q4	$363K	Sell	4,792 -14,671	-75%	-$1.28M	﹤0.01%	2316
2021 Q3	$2.18M	Sell	19,463 -2,919	-13%	-$367K	﹤0.01%	1575
2021 Q2	$3.62M	Sell	22,382 -7,152	-24%	-$870K	﹤0.01%	1451
2021 Q1	$3.6M	Sell	29,534 -8,088	-21%	-$1.22M	﹤0.01%	1459
2020 Q4	$5.76M	Buy	37,622 +5,273	+16%	+$623K	0.01%	1205
2020 Q3	$2.71M	Buy	32,349 +22,961	+245%	+$2.04M	﹤0.01%	1356
2020 Q2	$690K	Sell	9,388 -9,388	-50%	-$549K	﹤0.01%	1880
2020 Q1	$796K	Buy	18,776 +9,276	+98%	+$479K	﹤0.01%	1932
2019 Q4	$579K	Hold	9,500	–	–	﹤0.01%	1948
2019 Q3	$389K	Buy	+9,500	New	+$454K	﹤0.01%	1981
2019 Q1	–	Sell	-37,620	Closed	-$1.07M	–	1800
2018 Q4	$1.07M	Sell	37,620 -640	-2%	-$22.2K	﹤0.01%	1201
2018 Q3	$1.7M	Sell	38,260 -2,100	-5%	-$110K	﹤0.01%	1130
2018 Q2	$2.37M	Sell	40,360 -2,310	-5%	-$132K	0.01%	1042
2018 Q1	$1.95M	Buy	+42,670	New	+$1.76M	﹤0.01%	1074

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Victory Capital Management's CRSP Position: Q4 2022 in Review

Victory Capital Management sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 4,792 shares — an estimated $313K sold.

Victory Capital Management first reported a position in CRSP in Q1 2018 and held it in 17 quarters. The position peaked at $5.76M in Q4 2020. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

Victory Capital Management reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
Victory Capital Management sold 4,792 CRISPR Therapeutics shares in Q4 2022, an estimated $313K.
Victory Capital Management first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 17 quarters.
Victory Capital Management's CRISPR Therapeutics position peaked at $5.76M in Q4 2020.
398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Victory Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.